Current and future immunotherapeutic approaches in pancreatic cancer treatment
- PMID: 38835055
- PMCID: PMC11151541
- DOI: 10.1186/s13045-024-01561-6
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Abstract
Pancreatic cancer is a major cause of cancer-related death, but despondently, the outlook and prognosis for this resistant type of tumor have remained grim for a long time. Currently, it is extremely challenging to prevent or detect it early enough for effective treatment because patients rarely exhibit symptoms and there are no reliable indicators for detection. Most patients have advanced or spreading cancer that is difficult to treat, and treatments like chemotherapy and radiotherapy can only slightly prolong their life by a few months. Immunotherapy has revolutionized the treatment of pancreatic cancer, yet its effectiveness is limited by the tumor's immunosuppressive and hard-to-reach microenvironment. First, this article explains the immunosuppressive microenvironment of pancreatic cancer and highlights a wide range of immunotherapy options, including therapies involving oncolytic viruses, modified T cells (T-cell receptor [TCR]-engineered and chimeric antigen receptor [CAR] T-cell therapy), CAR natural killer cell therapy, cytokine-induced killer cells, immune checkpoint inhibitors, immunomodulators, cancer vaccines, and strategies targeting myeloid cells in the context of contemporary knowledge and future trends. Lastly, it discusses the main challenges ahead of pancreatic cancer immunotherapy.
Keywords: Adoptive cell therapy; CAR NK cell therapy; CAR T-cell therapy; Cancer vaccine; Immune checkpoint blockade; Immune checkpoint inhibitor; Oncolytic virus therapy; Pancreatic cancer immunotherapy; Pancreatic ductal adenocarcinoma.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11151541/bin/13045_2024_1561_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11151541/bin/13045_2024_1561_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11151541/bin/13045_2024_1561_Fig3_HTML.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11151541/bin/13045_2024_1561_Fig4_HTML.gif)
![Fig. 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11151541/bin/13045_2024_1561_Fig5_HTML.gif)
Similar articles
-
Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.Dig Dis Sci. 2021 Feb;66(2):359-368. doi: 10.1007/s10620-020-06183-9. Epub 2020 Mar 5. Dig Dis Sci. 2021. PMID: 32140943 Review.
-
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.Front Immunol. 2020 Apr 28;11:683. doi: 10.3389/fimmu.2020.00683. eCollection 2020. Front Immunol. 2020. PMID: 32411132 Free PMC article. Review.
-
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.JCI Insight. 2018 Apr 5;3(7):e99573. doi: 10.1172/jci.insight.99573. eCollection 2018 Apr 5. JCI Insight. 2018. PMID: 29618658 Free PMC article.
-
Immunotherapy for pancreatic ductal adenocarcinoma.J Surg Oncol. 2021 Mar;123(3):751-759. doi: 10.1002/jso.26312. J Surg Oncol. 2021. PMID: 33595893 Review.
-
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.Front Immunol. 2024 May 2;15:1383978. doi: 10.3389/fimmu.2024.1383978. eCollection 2024. Front Immunol. 2024. PMID: 38756774 Free PMC article. Review.
References
-
- Feng Y, Cai L, Pook M, Liu F, Chang C-H, Mouti MA, Nibhani R, Militi S, Dunford J, Philpott M, Fan Y, Fan G-C, Liu Q, Qi J, Wang C, Hong W, Morgan H, Wang M, Sadayappan S, Jegga AG, Oppermann U, Wang Y, Huang W, Jiang LPS. BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma. Gastroenterology. 2023;166:139–154. doi: 10.1053/j.gastro.2023.09.021. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical